secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001104659-24-001628
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024
-----------------------------------------------------------------------

- Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.
- Annual base salary of $450,000; signing bonus $195,000 with clawback if terminated for cause within one year.
- Target annual incentive for 2024 at 55% of base salary; equity grant includes 50,000 RSUs (4-yr vest, 1-yr cliff) plus 70,000 shares under exec comp programs.
- Laponis previously CFO at Eargo, VP at Tesla, VP/CFO at Cardinal Health, and held roles at Johnson & Johnson.
- No family relationships or related-party transactions with Laponis; disclosure via prior 8-K for Thorburn’s departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/tm2333797d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer